 |
PDF »
November 2, 2005
Cougar Biotechnology Announces Presentation at Rodman & Renshaw Techvest 7th Annual Healthcare Conference
Los Angeles, CA, November 2, 2005 - Cougar Biotechnology, Inc, a privately held biotechnology company, today announced that Alan H. Auerbach, Chief Executive Officer and President of Cougar, will present at the Rodman & Renshaw Techvest 7th Annual Healthcare Conference on Wednesday, November 9th at 8:20 AM EST at the New York Palace Hotel in New York, NY. Mr. Auerbach will provide a company overview and update on the status of Cougar's current clinical development programs.
A live webcast of the presentation can be accessed on the Company's website at www.cougarbiotechnology.com. The presentation will also be archived shortly after the live event and available online for 90 days following the conference.
About Cougar Biotechnology
Cougar Biotechnology, Inc. is a Los Angeles-based private biotechnology company established to in-license and develop clinical stage drugs, with a specific focus on the field of oncology. Cougar&39;s oncology portfolio includes CB7630, which has completed Phase I clinical trials in prostate cancer, CB3304, which is currently being tested in a Phase I trial in non-Hodgkin's lymphoma and CB1089, which has been clinically tested in a number of solid tumor types.
Further information about Cougar Biotechnology can be found at www.cougarbiotechnology.com.
Contact
Alan H. Auerbach
Cougar Biotechnology, Inc.
+1 310 443 4209
ahauerbach@cougarbiotechnology.com
This press release contains forward-looking statements that involve risks and uncertainties that could cause Cougar's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurances that any of Cougar's development efforts relating to its product candidates will be successful. Other risks that may affect forward-looking information contained in this press release include the possibility of being unable to obtain regulatory approval of Cougar's product candidates, the risk that the results of clinical trials may not support Cougar's claims, Cougar's reliance on third-party researchers to develop its product candidates and its lack of experience in developing pharmaceutical products. Cougar assumes no obligation to update these forward-looking statements, except as required by law.
| | |
Cougar Biotechnology, Inc.
10990 Wilshire Blvd, Suite 1200
Los Angeles, CA 90024
(310) 943-8040 Main
(310) 943-8059 Fax |
